Latest fiscal year 2025 · computed deterministically from XBRL 10-K data · coverage 100%
In fiscal 2025, NOVAVAX, INC. reported revenue of $1.12B, up 64.7% year over year. Operating margin was 40.3% and net margin 39.2%, on a free-cash-flow margin of -22.3% with capital expenditure at 0.5% of revenue. Every figure is computed directly from NVAX's SEC XBRL 10-K filing — deterministic, with no estimates.
| Fiscal year | Revenue | Op margin | Net margin |
|---|---|---|---|
| FY2025 | $1.12B | 40.3% | 39.2% |
| FY2024 | $682M | -36.5% | -27.5% |
| FY2023 | $984M | -57.6% | -55.4% |
| FY2022 | $1.98B | -32.5% | -33.2% |
| FY2021 | $1.15B | -147.1% | -152.1% |
How does NVAX compare against its actual peer set?
A CompsDesk subscription covers unlimited benchmark packs on any covered company: up to 19 metrics (6 core guaranteed) × up to 5 fiscal years × up to 12 chosen peers, percentile placement, the subject's figures cited to their SEC tag, form and period with every company identified by its CIK, PDF-ready HTML + CSV, generated on demand.
Related in the same sector: AAWH · ABBV · ABCL · ABT · ABUS · ACAD
Source: SEC EDGAR XBRL (10-K filings), latest filed values. "n/a" = not disclosed under mapped tags — never estimated. Informational benchmarking, not investment advice. © CompsDesk / Sam Arora.